

WEST

Generate Collection

Search Results - Record(s) 1 through 3 of 3 returned.**1. Document ID: US 6261560 B1**

L4: Entry 1 of 3

File: USPT

Jul 17, 2001

US-PAT-NO: 6261560

DOCUMENT-IDENTIFIER: US 6261560 B1

TITLE: Method for inhibiting muscle protein proteolysis with anti-interleukin-6 receptor

DATE-ISSUED: July 17, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Tsujinaka; Toshimasa	Ikoma	N/A	N/A	JPX
Ebisui; Chikasa	Ikeda	N/A	N/A	JPX
Fujita; Junya	Takatsuki	N/A	N/A	JPX

US-CL-CURRENT: 424/143.1; 424/130.1, 424/139.1, 424/141.1, 424/142.1, 514/921, 514/921, 530/387.1, 530/387.9, 530/388.1, 530/388.22

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	-----	-----------	-------

2. Document ID: US 5639455 A

L4: Entry 2 of 3

File: USPT

Jun 17, 1997

US-PAT-NO: 5639455

DOCUMENT-IDENTIFIER: US 5639455 A

TITLE: Immune suppressant

DATE-ISSUED: June 17, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Shimamura; Toshiro	Kawasaki	N/A	N/A	JPX
Nakazawa; Harumi	Kawasaki	N/A	N/A	JPX
Hamuro; Junji	Kawasaki	N/A	N/A	JPX

US-CL-CURRENT: 424/133.1; 424/130.1, 424/141.1, 424/141.1, 514/921, 514/921, 530/388.22

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	-----	-----------	-------

3. Document ID: US 5171837 A

L4: Entry 3 of 3

File: USPT

Dec 15, 1992

US-PAT-NO: 5171837

DOCUMENT-IDENTIFIER: US 5171837 A

TITLE: Peptide capable of binding interleukin 6 and an antibody comprising the peptide immobilized on a carrier

DATE-ISSUED: December 15, 1992

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Tanihara; Masao	Kurashiki	N/A	N/A	JPX
Oka; Kiichiro	Kurashiki	N/A	N/A	JPX

US-CL-CURRENT: 530/324; 530/325, 530/326, 530/810

Full	Title	Citation	Front	Review	Classification	Date	Reference
------	-------	----------	-------	--------	----------------	------	-----------

KMIC	Draw Desc	Image
------	-----------	-------

[Generate Collection](#)

Terms	Documents
il-6 with antibody with administration with receptor	3

[Display](#)[10](#) Documents, starting with Document: [3](#)**Display Format:** [CIT](#)[Change Format](#)

WEST☐ Generate Collection

L4: Entry 2 of 3

File: USPT

Jan 17, 1994

DOCUMENT-IDENTIFIER: US 5639455 A

TITLE: Immunosuppression

BSPR:

In fact, regarding some of the above mentioned diseases, the suppression of IL-6 in mouse model experiments has led to improvement in the diseases. For example, it has been reported that, by the administration of anti-mouse IL-6 antibody or anti-mouse IL-6 receptor antibody, which have an effect of suppressing the activity of mouse IL-6, to mice inoculated with myeloma cells, it is possible to both suppress the growth of myeloma cells and raise the survival rate of the mice (Journal of Experimental Medicine, vol. 172, p. 997 (1990)); that the metastasis of tumor cells to the liver may be suppressed by the administration of anti-mouse IL-6 antibody (Japanese Journal of Cancer Research, vol. 82, p. 1294 (1991)); that even mice infected with a lethal dose of E. coli survive when they are preadministered anti-mouse IL-6 antibody which suppresses the activity of mouse IL-6 (Journal of Immunology, vol. 145, p. 4185 (1990)), that when anti-mouse IL-6 antibody which possesses mouse IL-6-suppressing activity is administered to mouse models which develop cachexia when inoculated with tumor cells, an improvement is observed not only in the weight loss, but also in the symptoms of the cachexia (Journal of Clinical Investigation, vol. 89, p. 1661 (1992)), etc. These facts strongly indicate that IL-6 is connected with the above mentioned diseases. They also indicate that if the activity of human IL-6 can be suppressed, then a way may be provided for their treatment.

unfiled

WESTGenerate Collection

L4: Entry 1 of 3

File: USPT

Jul 17, 2001

DOCUMENT-IDENTIFIER: US 6261560 B1


TITLE: Method for inhibiting muscle protein proteolysis with antibodies to interleukin-6 receptor

DEPR:

Body weight including tumor weight, body weight excluding tumor weight (carcass weight) and gastrocnemius muscle weight on day 7 after the start of the experiment are shown in FIGS. 9, 10 and 11, respectively. Increases in carcass weight and gastrocnemius muscle weight were inhibited in the IL-6 receptor antibody administration group (there were no significant differences in body weight including tumor weight).

DEPR:

Cathepsin B activity and cathepsin B+L activity on day 17 of the experiment are shown in FIGS. 12 and 13, respectively. Increases in cathepsin B activity and cathepsin B+L activity observed over time were inhibited by administration of IL-6 receptor antibody (there were no significant differences observed regarding cathepsin B activity).



PubMed	Nucleotide	Protein	Genome	Structure	PopSet	Taxonomy	OMIM	
Search	PubMed	▼	for				Go	Clear
		Limits	Preview/Index	History	Clipboard			

Display	Abstract	▼	Save	Text	Order	Add to Clipboard
---------	----------	---	------	------	-------	------------------

1: Immunol Lett 1991 Sep;30(1):17-21

[Related Articles](#) [Books](#)

Anti-murine IL-6 receptor antibody inhibits IL-6 effects in vivo.

Suzuki H, Yasukawa K, Saito T, Anzai M, Goitsuka R, Hasegawa A, Ohsugi Y, Taga T, Kishimoto T.

Biotechnology Research Laboratory, Tosoh Corporation, Kanagawa, Japan.

Thrombopoiesis, as well as antibody production, is one of the major events in which interleukin-6 (IL-6) has been reported to be involved. Polyclonal anti-murine IL-6 receptor antibody was prepared to examine the effect of the antibody on these events in IL-6-treated mice. Administration of the anti-mIL-6R antibody inhibited the IL-6-induced increase in the number of platelets. Enhancement of the serum level of DNP-specific antibody by intraperitoneal injection of IL-6 was inhibited completely with simultaneous administration of the anti-mIL-6R antibody. The level of DNP-specific antibody was decreased, even below the basal value, by the higher dose of anti-mIL-6R antibody, indicating its effect also on endogenous IL-6. This work provides evidence that anti-IL-6R antibody inhibits IL-6 function in vivo, and provides an animal model of the therapeutic use of anti-IL-6R antibody for IL-6-related disease.

PMID: 1959939 [PubMed - indexed for MEDLINE]


Display	Abstract	▼	Save	Text	Order	Add to Clipboard
---------	----------	---	------	------	-------	------------------

[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Freedom of Information Act](#) | [Disclaimer](#)



PubMed	Nucleotide	Protein	Genome	Structure	PopSet	Taxonomy	OMIM	
Search	PubMed	▼	for				Go	Clear
		Limits	Preview/Index	History	Clipboard			

Display	Abstract	▼	Save	Text	Order	Add to Clipboard
---------	----------	---	------	------	-------	------------------

1: Eur J Immunol 1992 Aug;22(8):1989-93

[Related Articles](#), [Books](#), [LinkOut](#)

Anti-human interleukin-6 receptor antibody inhibits human myeloma growth in vivo.

Suzuki H, Yasukawa K, Saito T, Goitsuka R, Hasegawa A, Ohsugi Y, Taga T, Kishimoto T.

Biotechnology Research Laboratory, Tosoh Corporation, Kanagawa, Japan.

Myeloma is one of the interleukin (IL)-6-related diseases to which abnormal expression of IL-6 has been reported to be linked. We examined the in vivo inhibitory effect of anti-human IL-6 receptor (IL-6R) antibody on human myeloma cell growth in mice. SCID mice were subcutaneously inoculated with solid tumor of the myeloma cell line S6B45 in which human IL-6 was acting as an autocrine growth factor. Ten intraperitoneal administrations of 100 micrograms of the anti-human IL-6R antibody PM1 at 48-h intervals strongly inhibited the growth of S6B45 cells when the administration started 24 h after tumor inoculation. The tumor growth inhibition in vivo was also observed by administration of the anti-human IL-6 antibody MH166 using the same procedure as for PM1. The inhibitory effect of PM1 was not significant when the administration started 5 or more days after tumor inoculation. This work indicates that anti-human IL-6R antibody, as well as anti-human IL-6 antibody inhibits human myeloma growth in vivo, and provides an animal model for testing the therapeutic value of agents such as antibodies to human IL-6, IL-6R and gp130, an IL-6R-associated signal transducer, in the treatment of human myelomas.


PMID: 1639101 [PubMed - indexed for MEDLINE]

Display	Abstract	▼	Save	Text	Order	Add to Clipboard
---------	----------	---	------	------	-------	------------------

[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)
[Freedom of Information Act](#) | [Disclaimer](#)



PubMed	Nucleotide	Protein	Genome	Structure	PopSet	Taxonomy	OMIM
Search PubMed	▼ for					Go	Clear
Limits		Preview/Index		History		Clipboard	

Display	Abstract ▼	Save	Text	Order	Add to Clipboard
---------	------------	------	------	-------	------------------

1: Hybridoma 1993 Oct;12(5) 621-30

[Related Articles](#) [Books](#) [LinkOut](#)

A monoclonal anti-human IL-6 receptor antibody inhibits the proliferation of human myeloma cells.

Huang YW, Vitetta ES.


Department of Microbiology, University of Texas Southwestern Medical Center at Dallas 75235.

A monoclonal antibody (UV4) against the human IL-6 receptor (hIL-6R) was generated by immunizing BALB/c mice with both a human myeloma cell line (U266) and a murine cell line (M12.4/R) transfected with the hIL-6R cDNA. Flow cytometric analysis demonstrated that UV 4 stains the hIL-6R+ cell lines U266 and U937, but not the hIL-6R- cell lines Daudi and K562. Competitive inhibition assays demonstrated that preincubation of U266 cells with UV4 inhibited the binding of a phycoerythrin (PE)-IL-6 conjugate to the hIL-6R and also inhibited the proliferative activity of IL-6 on the IL-6-dependent human myeloma cell lines ILKM2 and ILKM3. In contrast, UV4 did not interfere with the proliferation of the hIL-6R- Burkitt's lymphoma cell line, Daudi. Direct sandwich radioimmunoassays further confirmed that the UV4 bound to the same molecule as the goat anti-hIL-6R antibody. These results suggest that both UV4 and human IL-6 bind to the same or adjacent epitopes on the hIL-6R. This monoclonal antibody should facilitate studies of the structure-function relationship of IL-6R and may be useful for the treatment of IL-6-dependent diseases such as multiple myeloma.

PMID: 8300137 [PubMed - indexed for MEDLINE]

Display	Abstract ▼	Save	Text	Order	Add to Clipboard
---------	------------	------	------	-------	------------------

[Write to the Help Desk](#)
NCBI | NLM | NIH
Department of Health & Human Services
[Freedom of Information Act](#) | [Disclaimer](#)



PubMed Nucleotide Protein Genome Structure PopSet Taxonomy OMIM

Search PubMed for

Limits Preview/Index History Clipboard

☐ 1: J Exp Med 1990 Sep 1;172(3):997-1000

[Related Articles](#) [Books](#)

Mouse plasmacytoma growth in vivo: enhancement by interleukin 6 (IL-6) and inhibition by antibodies directed against IL-6 or its receptor.

Vink A, Coulie P, Warnier G, Renauld JC, Stevens M, Donckers D, Van Snick J.

Ludwig Institute for Cancer Research, Brussels, Belgium.

Murine plasmacytomas show a striking dependence on interleukin 6 (IL-6) for their growth in vitro. Here, we present evidence suggesting that IL-6 also plays an essential role in the in vivo development of these tumors. This conclusion is based on the finding that the tumorigenicity of an IL-6-dependent plasmacytoma cell line was increased approximately 100-fold on transfection with an IL-6 expression vector, whereas it was inhibited in animals treated with monoclonal antibodies capable of blocking the binding of IL-6 to its receptor. Injection of these antibodies 1 d before tumor challenge protected greater than 50% of the mice and retarded tumor growth in all animals. Tumors arising in antibody-treated mice retained their IL-6 dependence in vitro, suggesting that the level of protection could be improved if stronger IL-6 antagonists were available.


PMID: 2388041 [PubMed - indexed for MEDLINE]

[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Freedom of Information Act](#) | [Disclaimer](#)



PubMed Nucleotide Protein Genome Structure PopSet Taxonomy OMIM

Search PubMed ▼ for [] Go Clear

Limits Preview/Index History Clipboard

Display Summary ▼ Save Text Order Add to Clipboard

Show: 20 ▼ Items 1-20 of 251 Page 1 of 13 Select page: 1 2 3 4 5 6 7 8 9 10 >>

1: [Vink A, Coulie P, Warnier G, Renauld JC, Stevens M, Donekers D, Van Snick J.](#) Related Articles

Mouse plasmacytoma growth in vivo: enhancement by interleukin 6 (IL-6) and inhibition by antibodies directed against IL-6 or its receptor.

J Exp Med. 1990 Sep 1;172(3):997-1000.

PMID: 2388041 [PubMed - indexed for MEDLINE]

2: [Coulie PG, Vink A, Van Snick J.](#) Related Articles

A monoclonal antibody specific for the murine IL-6-receptor inhibits the growth of a mouse plasmacytoma in vivo.

Curr Top Microbiol Immunol. 1990;166:43-6. No abstract available.

PMID: 2073815 [PubMed - indexed for MEDLINE]

3: [Suematsu S, Hibi M, Sugita T, Saito M, Murakami M, Matsusaka T, Matsuda T, Hirano T, Taga T, Kishimoto T.](#) Related Articles

Interleukin 6 (IL-6) and its receptor (IL-6R) in myeloma/plasmacytoma.

Curr Top Microbiol Immunol. 1990;166:13-22. Review. No abstract available.

PMID: 2073791 [PubMed - indexed for MEDLINE]

4: [Matsuda T, Hirano T.](#) Related Articles

Interleukin 6 (IL-6).

Biotherapy. 1990;2(4):363-73. Review. No abstract available.

PMID: 2268501 [PubMed - indexed for MEDLINE]

5: [Hirano T.](#) Related Articles

Interleukin 6 (IL-6) and its receptor: their role in plasma cell neoplasias.

Int J Cell Cloning. 1991 May;9(3):166-84. Review.

PMID: 2061619 [PubMed - indexed for MEDLINE]

6: [Shacter E, Arzadon G.](#) Related Articles

Elevation of IL-6 in plasma cell tumorigenesis.

AIDS Res Hum Retroviruses. 1992 May;8(5):754-6. Review. No abstract available.

PMID: 1515225 [PubMed - indexed for MEDLINE]

7: [Hopkins SJ, Rothwell NJ.](#) Related Articles

Further functions of IL-6.

Immunol Today. 1991 May;12(5):170. No abstract available.


PMID: 1750926 [PubMed - indexed for MEDLINE]

- 18:** [Shimamura T, Taki S, Honda H, Yokota M, Ito S, Takahara Y.](#) Related Articles
Analysis of interleukin 6 (IL-6)/IL-6 receptor system using monoclonal anti-IL-6 antibodies.
Mol Immunol. 1991 Nov;28(11):1155-61.
PMID: 1720500 [PubMed - indexed for MEDLINE]
- 19:** [Novick D, Shulman LM, Chen L, Revel M.](#) Related Articles
Enhancement of interleukin 6 cytostatic effect on human breast carcinoma cells by soluble IL-6 receptor from urine and reversion by monoclonal antibody.
Cytokine. 1992 Jan;4(1):6-11.
PMID: 1617157 [PubMed - indexed for MEDLINE]
- 10:** [Hirano T, Kishimoto T.](#) Related Articles
Interleukin 6 and plasma cell neoplasias.
Prog Growth Factor Res. 1989;1(3):133-42. Review.
PMID: 2491260 [PubMed - indexed for MEDLINE]
- 11:** [Okuno Y, Takahashi T, Suzuki A, Fukumoto M, Nakamura K, Fukui H, Koishihara Y, Ohsugi Y, Imura H.](#) Related Articles
Acquisition of growth autonomy and tumorigenicity by an interleukin 6-dependent human myeloma cell line transfected with interleukin 6 cDNA.
Exp Hematol. 1992 May;20(4):395-400.
PMID: 1568457 [PubMed - indexed for MEDLINE]
- 12:** [Brakenhoff JP, de Hon FD, Fontaine V, ten Boekel E, Schooltink H, Rose-John S, Heinrich PC, Content J, Aarden LA.](#) Related Articles
Development of a human interleukin-6 receptor antagonist.
J Biol Chem. 1994 Jan 7;269(1):86-93.
PMID: 8276883 [PubMed - indexed for MEDLINE]
- 13:** [Suzuki H, Yasukawa K, Saito T, Anzai M, Goitsuka R, Hasegawa A, Ohsugi Y, Taga T, Kishimoto T.](#) Related Articles
Anti-murine IL-6 receptor antibody inhibits IL-6 effects in vivo.
Immunol Lett. 1991 Sep;30(1):17-21.
PMID: 1959939 [PubMed - indexed for MEDLINE]
- 14:** [Kang HS, Cho DH, Kim SS, Pyun KH, Choi I.](#) Related Articles
Antitumor effects of IL-6 on murine liver tumor cells in vivo.
J Biomed Sci. 1999 Mar-Apr;6(2):142-4.
PMID: 10087445 [PubMed - indexed for MEDLINE]
- 15:** [Yokoyama A.](#) Related Articles
[Interleukin-6 (IL-6)].
Nippon Rinsho. 1995 Mar;53 Suppl 2:790-3. Review. Japanese. No abstract available.
PMID: 8753360 [PubMed - indexed for MEDLINE]
- 16:** [Jernberg-Wiklund H, Pettersson M, Carlsson M, Nilsson K.](#) Related Articles
Increase in interleukin 6 (IL-6) and IL-6 receptor expression in a human multiple myeloma cell line, U-266, during long-term in vitro culture and the

development of a possible autocrine IL-6 loop.

Leukemia. 1992 Apr;6(4):310-8.

PMID: 1588793 [PubMed - indexed for MEDLINE]

-  **17:** [Suzuki H, Yasukawa K, Saito T, Goitsuka R, Hasegawa A, Ohsugi Y, Taga T, Kishimoto T](#) [Related Articles](#)

Anti-human interleukin-6 receptor antibody inhibits human myeloma growth in vivo.

Eur J Immunol. 1992 Aug;22(8):1989-93.


PMID: 1639101 [PubMed - indexed for MEDLINE]

-  **18:** [Hirano T, Akira S, Taga T, Kishimoto T](#) [Related Articles](#)

Biological and clinical aspects of interleukin 6.

Immunol Today. 1990 Dec;11(12):443-9. Review.


PMID: 2127356 [PubMed - indexed for MEDLINE]

-  **19:** [Tohyama N, Karasuyama H, Tada T](#) [Related Articles](#)

Growth autonomy and tumorigenicity of interleukin 6-dependent B cells transfected with interleukin 6 cDNA.

J Exp Med. 1990 Feb 1;171(2):389-400.

PMID: 2303779 [PubMed - indexed for MEDLINE]


-  **20:** [Hirano T, Taga T, Yamasaki K, Matsuda T, Tang B, Muraguchi A, Horii Y, Suematsu S, Hirata Y, Yawata H, et al](#) [Related Articles](#)

A multifunctional cytokine (IL-6/BSF-2) and its receptor.

Int Arch Allergy Appl Immunol. 1989;88(1-2):29-33. Review.

PMID: 2651317 [PubMed - indexed for MEDLINE]

[Display](#) [Summary](#)  [Save](#) [Text](#) [Order](#) [Add to Clipboard](#)


Show:  Items 1-20 of 251 Page 1 of 13 Select page: [1](#) [2](#) [3](#) [4](#) [5](#) [6](#) [7](#) [8](#) [9](#) [10](#) >>

[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Freedom of Information Act](#) | [Disclaimer](#)



PubMed	Nucleotide	Protein	Genome	Structure	PopSet	Taxonomy	OMIM
Search PubMed	for					Go	Clear
Limits		Preview/Index		History		Clipboard	

Display	Summary	Save	Text	Order	Add to Clipboard
---------	---------	------	------	-------	------------------

Show: 20 Items 1-20 of 134 Page 1 of 7 Select page: 1 2 3 4 5 6 7

- 1: [Suzuki H, Yasukawa K, Saito T, Anzai M, Goitsuka R, Hasegawa A, Ohsugi Y, Taga T, Kishimoto T.](#) Related Articles
Anti-murine IL-6 receptor antibody inhibits IL-6 effects in vivo.
Immunol Lett. 1991 Sep;30(1):17-21.
PMID: 1959939 [PubMed - indexed for MEDLINE]
- 2: [Coulie PG, Vink A, Van Snick J.](#) Related Articles
A monoclonal antibody specific for the murine IL-6-receptor inhibits the growth of a mouse plasmacytoma in vivo.
Curr Top Microbiol Immunol. 1990;166:43-6. No abstract available.
PMID: 2073815 [PubMed - indexed for MEDLINE]
- 3: [Suzuki H, Yasukawa K, Saito T, Goitsuka R, Hasegawa A, Ohsugi Y, Taga T, Kishimoto T.](#) Related Articles
Anti-human interleukin-6 receptor antibody inhibits human myeloma growth in vivo.
Eur J Immunol. 1992 Aug;22(8):1989-93.
PMID: 1639101 [PubMed - indexed for MEDLINE]
- 4: [Vink A, Coulie P, Warnier G, Renauld JC, Stevens M, Donckers D, Van Snick J.](#) Related Articles
Mouse plasmacytoma growth in vivo: enhancement by interleukin 6 (IL-6) and inhibition by antibodies directed against IL-6 or its receptor.
J Exp Med. 1990 Sep 1;172(3):997-1000.
PMID: 2388041 [PubMed - indexed for MEDLINE]
- 5: [Montero-Julian FA, Liautard J, Flavetta S, Romagne F, Gaillard JP, Brochier J, Klein B, Brailly H.](#) Related Articles
Immunoassay for functional human soluble interleukin-6 receptor in plasma based on ligand/receptor interactions.
J Immunol Methods. 1994 Feb 28;169(1):111-21.
PMID: 8133069 [PubMed - indexed for MEDLINE]
- 6: [Shinkura H, Imazeki I, Yamazaki M, Oda Y, Kotoh M, Mihara M.](#) Related Articles
In vivo blocking effects of a humanized antibody to human interleukin-6 receptor on interleukin-6 function in primates.
Anticancer Res. 1998 Mar-Apr;18(2A):1217-21.
PMID: 9615791 [PubMed - indexed for MEDLINE]

- 7: [Saito T, Yasukawa K, Suzuki H, Futatsugi K, Fukunaga T, Yokomizo C, Koishihara Y, Fukui H, Ohsugi Y, Yawata H, et al.](#) Related Articles
Preparation of soluble murine IL-6 receptor and anti-murine IL-6 receptor antibodies.
J Immunol. 1991 Jul 1;147(1):168-73.
PMID: 2051018 [PubMed - indexed for MEDLINE]
- 8: [Novick D, Shulman LM, Chen L, Revel M.](#) Related Articles
Enhancement of interleukin 6 cytostatic effect on human breast carcinoma cells by soluble IL-6 receptor from urine and reversion by monoclonal antibody.
Cytokine. 1992 Jan;4(1):6-11.
PMID: 1617157 [PubMed - indexed for MEDLINE]
- 9: [Ishibashi T, Kimura H, Shikama Y, Uchida T, Kariyone S, Hirano T, Kishimoto T, Takatsuki F, Akiyama Y.](#) Related Articles
Interleukin-6 is a potent thrombopoietic factor in vivo in mice.
Blood. 1989 Sep;74(4):1241-4.
PMID: 2788464 [PubMed - indexed for MEDLINE]
- 10: [Goto H, Shimazaki C, Tatsumi T, Yamagata N, Hirata T, Ashihara E, Oku N, Inaba T, Fujita N, Koishihara Y, et al.](#) Related Articles
Mouse anti-human interleukin-6 receptor monoclonal antibody inhibits proliferation of fresh human myeloma cells in vitro.
Jpn J Cancer Res. 1994 Sep;85(9):958-65.
PMID: 7961126 [PubMed - indexed for MEDLINE]
- 11: [Saggio I, Ciapponi L, Savino R, Ciliberto G, Perricaudet M.](#) Related Articles
Adenovirus-mediated gene transfer of a human IL-6 antagonist.
Gene Ther. 1997 Aug;4(8):839-45.
PMID: 9338013 [PubMed - indexed for MEDLINE]
- 12: [Fu J, Zheng J, Fang W, Wu B.](#) Related Articles
Effect of interleukin-6 on the growth of human lung cancer cell line.
Chin Med J (Engl). 1998 Mar;111(3):265-8.
PMID: 10374431 [PubMed - indexed for MEDLINE]
- 13: [Schobitz B, Pezeshki G, Pohl T, Hemmann U, Heinrich PC, Holsboer E, Reul JM.](#) Related Articles
Soluble interleukin-6 (IL-6) receptor augments central effects of IL-6 in vivo.
FASEB J. 1995 May;9(8):659-64.
PMID: 7768358 [PubMed - indexed for MEDLINE]
- 14: [Fu J, Zheng J, Fang W.](#) Related Articles
[Interleukin-6 behaves as an autocrine growth stimulator for a human lung giant cell carcinoma cell line].
Zhonghua Bing Li Xue Za Zhi. 1997 Feb;26(1):5-7. Chinese.
PMID: 10072840 [PubMed - indexed for MEDLINE]
- 15: [Huang YW, Vitetta ES.](#) Related Articles
A monoclonal anti-human IL-6 receptor antibody inhibits the proliferation of

human myeloma cells.
Hybridoma. 1993 Oct;12(5):621-30.
PMID: 8300137 [PubMed - indexed for MEDLINE]

16: [Geisterfer M, Richards C, Baumann M, Fey G, Gwynne D, Gauldie J](#) Related Articles

Regulation of IL-6 and the hepatic IL-6 receptor in acute inflammation in vivo.
Cytokine. 1993 Jan;5(1):1-7.
PMID: 7683503 [PubMed - indexed for MEDLINE]

17: [Yoshizaki K, Nishimoto N, Matsumoto K, Tagoh H, Taga T, Deguchi Y, Kuritani T, Hirano T, Hashimoto K, Okada N, et al](#) Related Articles

Interleukin 6 and expression of its receptor on epidermal keratinocytes.
Cytokine. 1990 Sep;2(5):381-7.
PMID: 2129417 [PubMed - indexed for MEDLINE]

18: [Suematsu S, Hibi M, Sugita T, Saito M, Murakami M, Matsusaka T, Matsuda T, Hirano T, Taga T, Kishimoto T](#) Related Articles

Interleukin 6 (IL-6) and its receptor (IL-6R) in myeloma/plasmacytoma.
Curr Top Microbiol Immunol. 1990;166:13-22. Review. No abstract available.
PMID: 2073791 [PubMed - indexed for MEDLINE]

19: [Shacter E, Arzadon G](#) Related Articles

Elevation of IL-6 in plasma cell tumorigenesis.
AIDS Res Hum Retroviruses. 1992 May;8(5):754-6. Review. No abstract available.
PMID: 1515225 [PubMed - indexed for MEDLINE]

20: [Kang HS, Cho DH, Kim SS, Pyun KH, Choi J](#) Related Articles

Antitumor effects of IL-6 on murine liver tumor cells in vivo.
J Biomed Sci. 1999 Mar-Apr;6(2):142-4.
PMID: 10087445 [PubMed - indexed for MEDLINE]

Display **Summary** ☐ **Save** **Text** **Order** **Add to Clipboard**
Show: **20** ☐ Items 1-20 of 134 Page 1 of 7 Select page: 1 2 3 4 5 6 7

[Write to the Help Desk](#)
[NCBI](#) | [NLM](#) | [NIH](#)
[Department of Health & Human Services](#)
[Freedom of Information Act](#) | [Disclaimer](#)